Physician profile
Robert Wiskocil
NPI 1992883094
$2,179.68
in general payments reported to CMS, 2019-2025
11 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $299 · 2021: $23.45 · 2022: $66.29 · 2023: $558 · 2024: $204 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.51 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $522.02 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $232.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $151.47 | 2019-2020 | |
| Horizon Therapeutics Plc | $147.87 | 2019 | |
| Optinose US, INC. | $126.49 | 2020 | |
| Glaxosmithkline, LLC. | $122.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $78.72 | 2019 | |
| Siemens Medical Solutions USA, INC. | $66.29 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $57.03 | 2023 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wiskocil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.